167 related articles for article (PubMed ID: 34801827)
1. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
2. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
[TBL] [Abstract][Full Text] [Related]
4. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
7. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
9. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors.
Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE
ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
11. Live-cell studies of p300/CBP histone acetyltransferase activity and inhibition.
Dancy BM; Crump NT; Peterson DJ; Mukherjee C; Bowers EM; Ahn YH; Yoshida M; Zhang J; Mahadevan LC; Meyers DJ; Boeke JD; Cole PA
Chembiochem; 2012 Sep; 13(14):2113-21. PubMed ID: 22961914
[TBL] [Abstract][Full Text] [Related]
12. 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors.
Kanada R; Suzuki T; Murata T; Miyazaki M; Shimada T; Kuroha M; Minami M; Higuchi S; Tominaga Y; Naito H
Bioorg Med Chem Lett; 2021 Nov; 51():128358. PubMed ID: 34534674
[TBL] [Abstract][Full Text] [Related]
13. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity.
Stimson L; Rowlands MG; Newbatt YM; Smith NF; Raynaud FI; Rogers P; Bavetsias V; Gorsuch S; Jarman M; Bannister A; Kouzarides T; McDonald E; Workman P; Aherne GW
Mol Cancer Ther; 2005 Oct; 4(10):1521-32. PubMed ID: 16227401
[TBL] [Abstract][Full Text] [Related]
14. Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism.
Cai LY; Chen SJ; Xiao SH; Sun QJ; Ding CH; Zheng BN; Zhu XY; Liu SQ; Yang F; Yang YX; Zhou B; Luo C; Zhang X; Xie WF
Cancer Res; 2021 Feb; 81(4):860-872. PubMed ID: 33361394
[TBL] [Abstract][Full Text] [Related]
15. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
16. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
Shirakawa K; Wang L; Man N; Maksimoska J; Sorum AW; Lim HW; Lee IS; Shimazu T; Newman JC; Schröder S; Ott M; Marmorstein R; Meier J; Nimer S; Verdin E
Elife; 2016 May; 5():. PubMed ID: 27244239
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
18. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
19. Probing the reaction coordinate of the p300/CBP histone acetyltransferase with bisubstrate analogs.
Karukurichi KR; Cole PA
Bioorg Chem; 2011 Feb; 39(1):42-7. PubMed ID: 21111442
[TBL] [Abstract][Full Text] [Related]
20. Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT.
Liu Y; Yang EJ; Shi C; Mou PK; Zhang B; Wu C; Lyu J; Shim JS
Int J Biol Sci; 2020; 16(11):1774-1784. PubMed ID: 32398948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
